Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated November 8, 2024, discloses a transaction involving the company's shares by a person discharging managerial responsibilities. The filing is made pursuant to Article 19 of Regulation No. 596/2014 on market abuse. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It solely reports on a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Sale of Shares |
| Instrument | Novo Nordisk B Shares (DK0062498333) |
| Volume | 6,311,250 shares |
| Price per Share | DKK 750.42 |
| Total Value | DKK 4,736,088,225.00 |
| Transaction Date | November 8, 2024 |
| Place of Transaction | Outside a trading venue |
Material Changes
The filing does not provide comparative financial data or material changes to the company's operations versus prior periods. The only reported change is the reduction in shareholding by the associated entity.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of insider trading activity.
Important Facts for Investors
- Seller Identity: The shares were sold by Novo Holdings A/S, which is associated with Kasim Kutay, a Member of the Board of Directors.
- Transaction Scale: The sale involved over 6.3 million shares, representing a significant volume transaction valued at approximately DKK 4.7 billion.
- Execution Method: The transaction was executed outside of a standard trading venue.
- Regulatory Basis: The disclosure is mandatory under EU market abuse regulations regarding transactions by persons discharging managerial responsibilities.